Stability of Metronidazole Free-base Oral Suspensions Formulated with United States Pharmacopeia-grade Metronidazole Powder and Commercial Metronidazole Tablets
Author(s): Jarouche Marian, Ibrahim Martha, Pearson Jarryd, Low Mitchell, Rowe James
Issue: Jan/Feb 2020 - Volume 24, Number 1
View All Articles in Issue
Page(s): 77-82
Download in electronic PDF format for $75
Abstract: This study reports on the stability of United States Pharmacopeia-grade metronidazole powder and commercially available metronidazole tablets in two dye-free oral suspending vehicles, namely Oral Mix and Oral Mix Sugar-Free. Metronidazole at 50 mg/mL was prepared individually in Oral Mix and Oral Mix Sugar-Free suspension vehicles and placed in 50-mL amber polyethyleneterephthalate bottles and 3-mL amber plastic syringes and stored at 4°C or 25°C/60% relative humidity for 90 days. The solutions were analyzed at the time of preparation and at 7 days, 14 days, 30 days, 45 days, 60 days, 75 days, and 90 days, with the concentration of metronidazole measured by high-performance liquid chromatography with photodiode array detection. The oral solutions were also monitored for pH, homogeneity, color, and odor. Except for the Oral Mix suspension of metronidazole prepared from the United States Pharmacopeia-grade powder and from the commercial tablet, when stored in pre-filled syringes, all the other preparations were stable at 4°C or 25°C/60% relative humidity for 90 days, with the metronidazole remaining within ± 10% of the initial concentration. The pH, color, odor, and resuspendability remained essentially unchanged. Metronidazole in Oral Mix and Oral Mix Sugar-Free oral suspensions, compounded from United States Pharmacopeia-grade powder or commercially available tablets, are a suitable alternative as an extemporaneously prepared medication.
Related Keywords:
Marian Jarouche, PhD, Martha Ibrahim, BBioTech, Jarryd Pearson, BMedSc, Beatrice Venkataya, MRes, Mitchell Low, PhD, James Rowe, PhD, metronidazole, antibiotic, antimicrobial agent, stability, packaging, storage, oral suspensions
Related Categories:
PEER-REVIEWED, STABILITIES, COMPATIBILITIES, UNITED STATES PHARMACOPEIA CONVENTIONS, INFECTIOUS DISEASE
Printer-Friendly Version
Related Articles from IJPC |
Title/Author
(Click for Abstract / Details / Purchase) |
Issue/Page
View/Buy |
Stability of Metronidazole Free-base Oral Suspensions Formulated with United States Pharmacopeia-grade Metronidazole Powder and Commercial Metronidazole Tablets
Jarouche Marian, Ibrahim Martha, Pearson Jarryd, Low Mitchell, Rowe James
|
Jan/Feb 2020
Pg. 77-82
|
Physicochemical and Microbiological Stability of Compounded Metronidazole Suspensions in PCCA SuspendIt
Pramar Yashoda V, Mandal Tarun K, Bostanian Levon A, Le Giang, Morris Tommy C, Graves Richard A
|
Mar/Apr 2021
Pg. 169-175
|
Case Report: The Quest for a Palatable Compounded Metronidazole (Base) Suspension
McElhiney Linda F
|
Jan/Feb 2021
Pg. 24-28
|
Metronidazole 50-mg/mL in Oral Mix and Oral Mix SF Suspension
Allen Loyd V Jr
|
Jan/Feb 2021
Pg. 47
|
Stability of Metronidazole Benzoate in SyrSpend SF One-Step Suspension System
Vu Nicole T, Aloumanis Vasileios, Ben Michel J, Kupiec Thomas C, Patterson Evelyn K, Radke Joshua, Erickson Martin A III, Schneider Gary
|
Nov/Dec 2008
Pg. 558-564
|
PreScription: Formal Appeals to United States Pharmacopeia Regarding USP Chapters <795>,<797>, and <825>: Part 1
Allen Loyd V Jr
|
Mar/Apr 2020
Pg. 92
|
PreScription: Formal Appeals to United States Pharmacopeia Regarding USP Chapters <795>, <797>, and <825>: Part 2
Allen Loyd V Jr
|
May/Jun 2020
Pg. 180
|
Stability of Metronidazole Suspensions
Donnelly Ronald F, Ying James
|
May/Jun 2015
Pg. 248-251
|
PreScription: Stability Studies and United States Pharmacopeia-National Formulary-Grade Chemicals
Allen Loyd V Jr
|
Sep/Oct 2016
Pg. 356
|
Metronidazole Benzoate 70 mg/mL in SyrSpend SF Oral Suspension
Allen Loyd V Jr
|
Jul/Aug 2018
Pg. 320
|
Quality Control: Minor Chapters, Major Impacts: What United States Pharmacopeia Chapters <51>, <61>, <62>, and <1207> Mean for Your Compounding Practice
Kelley Brian
|
Mar/Apr 2021
Pg. 115-124
|
Metronidazole 50 mg/mL in Ora-Blend Suspension
Allen Loyd V Jr
|
Jan/Feb 2018
Pg. 52
|
Compatibility and Stability of Palonosetron Hydrochloride with Gentamicin, Metronidazole, or Vancomycin During Simulated Y-Site Administration
Kupiec Thomas C, Ben Michel, Trusley Craig, Trissel Lawrence A
|
Mar/Apr 2008
Pg. 170-173
|
Metronidazole in Normal Saline Enema
Allen Loyd V Jr
|
Jan/Feb 2010
Pg. 69
|
Metronidazole 5-mg/mL Injection
Allen Loyd V Jr
|
Sep/Oct 2012
Pg. 425
|
Lidocaine 2%, Metronidazole 2%, Misoprostol 0.0024% Topical Ointment
Allen Loyd V Jr
|
Sep/Oct 2015
Pg. 406
|
Hydrocortisone 2%, Iodoquinol 1% Metronidazole 10%, and Zinc Oxide 2% in Polyethylene Glycol Ointment
Allen Loyd V Jr
|
Jan/Feb 2020
Pg. 57
|
Metronidazole 7.5 mg/mL Topical Oil-in-Water Microemulsion
Allen Loyd V Jr
|
May/Jun 2022
Pg. 238
|
Metronidazole 10%, Nifedipine 0.5%, Lidocaine 1.5%, and Diclofenac 3% Ointment
Allen Loyd V Jr
|
Sep/Oct 2022
Pg. 430
|
Use of Topical Metronidazole in the Treatment of Anorectal Crohn's Disease
McElhiney Linda F
|
Sep/Oct 2013
Pg. 380-383
|
Return to Top |